Meridian Bioscience (Meridian Bioscience) Total Inventories : $67.8 Mil (As of Sep. 2022)

View and export this data going back to 1986. Start your Free Trial

What is Meridian Bioscience Total Inventories?

Meridian Bioscience's total inventories for the quarter that ended in Sep. 2022 was $67.8 Mil. Meridian Bioscience's average total inventories from the quarter that ended in Jun. 2022 to the quarter that ended in Sep. 2022 was $69.0 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Meridian Bioscience's Net-Net Working Capital per share for the quarter that ended in Sep. 2022 was $1.27.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Meridian Bioscience's Days Inventory for the three months ended in Sep. 2022 was 198.61.

Inventory Turnover measures how fast the company turns over its inventory within a year. Meridian Bioscience's Inventory Turnover for the quarter that ended in Sep. 2022 was 0.46.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Meridian Bioscience's Inventory-to-Revenue for the quarter that ended in Sep. 2022 was 1.05.

Meridian Bioscience Total Inventories Historical Data

The historical data trend for Meridian Bioscience's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meridian Bioscience Total Inventories Chart

Meridian Bioscience Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Total Inventories

Get a 7-Day Free Trial

41.99

39.62

61.26

76.84

67.81

Meridian Bioscience Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
Total Inventories	Get a 7-Day Free Trial															76.84	74.20	70.93	70.11	67.81

Meridian Bioscience Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Meridian Bioscience (NAS:VIVO) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Meridian Bioscience's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2022 is

	Net-Net Working Capital Per Share (Q: Sep. 2022 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(81.453	+	0.75 * 47.235	+	0.5 * 67.814	-	95.036
-	0	-	0)	/	43.7455
=	1.27

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Meridian Bioscience's Days Inventory for the three months ended in Sep. 2022 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Sep. 2022 )	/	Cost of Goods Sold (Q: Sep. 2022 )	*	Days in Period
	=	68.9595	/	31.683	*	365 / 4
	=	198.61

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Meridian Bioscience's Inventory Turnover for the quarter that ended in Sep. 2022 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Sep. 2022 )	/	Average Total Inventories (Q: Sep. 2022 )
	=	31.683	/	68.9595
	=	0.46

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Meridian Bioscience's Inventory to Revenue for the quarter that ended in Sep. 2022 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Sep. 2022 )	/	Revenue (Q: Sep. 2022 )
	=	68.9595	/	65.675
	=	1.05

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Meridian Bioscience Total Inventories Related Terms

Thank you for viewing the detailed overview of Meridian Bioscience's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Meridian Bioscience (Meridian Bioscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Meridian Bioscience Inc (NAS:VIVO) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

N/A

Address

3471 River Hills Drive, Cincinnati, OH, USA, 45244

Website

https://www.meridianbioscience.com

Meridian Bioscience Inc is an integrated life science company. It develops and distributes diagnostic tests and reagents, as well as biologic substances used by pharmaceutical and biotechnology companies. Its Diagnostics segment manufactures tests primarily for gastrointestinal, viral, respiratory, & parasitic infectious diseases. Its testing platforms include isothermal DNA amplification, rapid immunoassays, and enzyme-linked immunoassays. The Life sciences segment sells b-antigens, antibodies, and reagents in bulk to other diagnostic manufacturers, the agriculture industry, and researchers. It also manufactures proteins that biopharmaceutical companies use in new drugs and vaccines. The entity has a business presence in the US and other countries.

Executives

Julie Diana Smith	officer: Sr VP, Controller, PAO	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
John P. Kenny	director, officer: Chief Executive Officer	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Andrew S. Kitzmiller	officer: EVP & CFO	ONE BATESVILLE BLVD., BATESVILLE IN 47006
Bryan T Baldasare	officer: Interim CFO & Chief Acctg Off	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Rice John Mccune Jr.	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Bihl Anthony P Iii	director	807 SMITH RIDGE ROAD, NEW CANAAN CT 06840
Tony Serafini-lamanna	officer: Executive VP-Diagnostics	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Felicia Williams	director	C/O MACY'S, INC., 151 WEST 34TH STREET, NEW YORK NY 10001
John Mcilwraith	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
David Phillips	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
James M. Anderson	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Dwight E Ellingwood	director	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lawrence Baldini	officer: Exec VP, Operations & IS	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Eric S. Rasmussen	officer: EVP, Bus. Development/Strategy	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244
Lourdes Weltzien	officer: EVP, Life Science	3471 RIVER HILLS DRIVE, CINCINNATI OH 45244